Skip to main content

Table 2 Examples of targeted therapies currently undergoing clinical testing in NSCLC

From: Clinical potential of gene mutations in lung cancer

Study name/identifiera Purpose Targeted therapies
Pilot trial of molecular profiling and targeted therapy for advanced NSCLC, SCLC, and thymic malignancies
NCT01306045
Evaluate the ability of genetic analysis to determine targeted therapy for patients with NSCLC AZD6244 MEK1 inhibitor for KRAS or BRAF mutations
MK-2206 AKT inhibitor for PIK3CA, AKT, PTEN mutations
Sunitib inhibitor for KIT or PDGFRA mutations
Lapatinib inhibitor for ERBB2
Erlotinib inhibitor for EGFR mutations
Evaluation of the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic NSCLC
NCT02117167
Evaluate the use of high throughput genome analysis to determine administration of targeted therapy according to genetic profile of the tumor compared to standard treatment. Randomized multicenter Phase II trial AZD2014 inhibitor for m-TOR
AZD4547 inhibitor for FGFR
AZD5363 inhibitor for AKT,
AZD8931 inhibitor for EGFR
Selumetinib inhibitor for MEK1
Vandetanib inhibitor for VEGFR and EGFR
FGFR1 amplification as a predictor of efficacy in a biomarker-driven phase II study of BIBF 1120 in advanced lung SCC patients who have failed up to 2 prior chemotherapeutic regimens
NCT01948141
Evaluate efficacy of nintedanib in treating patients with advanced NSCLC who failed up to two previous chemotherapy regimens and use of FGFR1 gene copy number is a predictive biomarker Nintedanib TKI for FGFR1
  1. AKT v-akt murine thymoma vial oncogene homolog 1, BRAF v-raf murine sarcoma viral oncogene homolog B, EGFR epidermal growth factor receptor, FGFR1 fibroblast growth factor receptor 1, KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog, MEK mitogen-activated protein kinase kinase 1, m-TOR mechanistic target of rapamycin, NSCLC non-small cell lung carcinoma, SCC squamous cell carcinoma, SCLC small cell lung carcinoma, VEGF vascular endothelial growth factor, VEGFR vascular endothelial growth factor receptor
  2. aDenotes http://www.clinicaltrials.gov identifier